Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.
Why it matters
The trial provides randomized evidence that a chemotherapy-free combination of a tyrosine kinase inhibitor and immunotherapy can improve event-free survival compared with an imatinib–chemotherapy regimen in adults with…